Clinical Study on Ultrasound-Guided Guanci for Lateral Epicondylitis

注册号:

Registration number:

ITMCTR2025001055

最近更新日期:

Date of Last Refreshed on:

2025-05-27

注册时间:

Date of Registration:

2025-05-27

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

超声引导贯刺治疗肱骨外上髁炎的临床研究

Public title:

Clinical Study on Ultrasound-Guided Guanci for Lateral Epicondylitis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导贯刺治疗肱骨外上髁炎的临床研究

Scientific title:

Clinical Study on Ultrasound-Guided Guanci for Lateral Epicondylitis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张文韬

研究负责人:

刘昊

Applicant:

Wentao Zhang

Study leader:

Hao liu

申请注册联系人电话:

Applicant telephone:

19857168960

研究负责人电话:

Study leader's telephone:

15868814927

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1262630344@qq.com

研究负责人电子邮件:

Study leader's E-mail:

Haoliu1987@aliyun.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市西湖区古翠路234号浙江省立同德医院翠苑院区

研究负责人通讯地址:

浙江省杭州市西湖区古翠路234号浙江省立同德医院翠苑院区

Applicant address:

Tongde Hospital of Zhejiang Province No. 234 Gucui Road Xihu District Hangzhou Zhejiang Province China

Study leader's address:

Tongde Hospital of Zhejiang Province No. 234 Gucui Road Xihu District Hangzhou Zhejiang Province China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中西医结合临床医学院,浙江中医药大学

Applicant's institution:

The Integrated Traditional Chinese and Western Medicine School of Clinical Medicne Zhejiang Chinese Medical University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

浙同德伦审2024研第036号

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

浙江省立同德医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Tongde Hospital of Zhejiang Province

伦理委员会批准日期:

Date of approved by ethic committee:

2024/11/22 0:00:00

伦理委员会联系人:

朱于青

Contact Name of the ethic committee:

Yuqing Zhu

伦理委员会联系地址:

杭州市西湖区古翠路234号6号楼302

Contact Address of the ethic committee:

302 Building 6 No.234 Gucui Road Xihu District Hangzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

0571-89975971

伦理委员会联系人邮箱:

Contact email of the ethic committee:

tongdelunli@163.com

研究实施负责(组长)单位:

浙江省立同德医院

Primary sponsor:

Tongde Hospital of Zhejiang Province

研究实施负责(组长)单位地址:

浙江省杭州市西湖区古翠路234号浙江省立同德医院翠苑院区

Primary sponsor's address:

Tongde Hospital of Zhejiang Province No. 234 Gucui Road Xihu District Hangzhou Zhejiang Province China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州市

Country:

China

Province:

Zhejiang Province

City:

Hangzhou

单位(医院):

浙江省立同德医院

具体地址:

浙江省杭州市西湖区古翠路234号浙江省立同德医院翠苑院区

Institution
hospital:

Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University

Address:

Tongde Hospital of Zhejiang Province ,No. 234 Gucui Road,Xihu District,Hangzhou, Zhejiang Province China

经费或物资来源:

国家自然基金

Source(s) of funding:

National Natural Science Foundation of China

研究疾病:

肱骨外上髁炎

研究疾病代码:

Target disease:

Lateral Epicondylitis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

基于在超声引导下贯刺治疗肱骨外上髁炎,意在将现代医疗设备与刃针疗法相结合,做到安全有效针刺的同时明确贯刺筋结点的操作有效性,减少临床无效针刺,形成一整套超声引导针刺治疗肱骨外上髁炎的规范化技术方案,便于推广应用。

Objectives of Study:

Ultrasound-Guided Guanci for Lateral Epicondylitis: Integrating Modern Medical Devices with Blade Needle Therapy.This study aims to combine modern medical equipment with blade needle therapy ensuring safe and effective acupuncture while clarifying the operational efficacy of penetrating tendon nodes. By reducing clinically ineffective needling practices the research seeks to establish a standardized technical protocol for ultrasound-guided acupuncture in treating lateral epicondylitis facilitating widespread clinical application.

药物成份或治疗方案详述:

研究以符合条件的肱骨外上髁炎患者为研究对象,采用随机对照的研究方法,随机分为两组,分别在超声引导下针刺患侧手三里、四渎穴患肌的浅筋膜层和深筋膜层。用视觉模拟量表(Visual Analogue Scale/Score,VAS)评分、握力指数、Mayo肘关节功能评分(Mayo elbow performance score,MEPS)、压痛阈值(PPT)、整体疗效评分作为评价指标,分别于治疗前、治疗后及1个月后进行随访,进行数据分析、临床疗效及安全性评价。证明超声引导贯刺可有效治疗肱骨外上髁炎,并且明确针刺结筋病灶点的有效操作。

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合肱骨外上髁炎的诊断标准。②年龄18-65周岁,不限制性别。③肘部疼痛时间6个月以内者。④肱骨外上髁处压痛视觉模拟量表(VAS)评分≥4。⑤单侧肘部受累者⑥能够配合完成各种肱骨外上髁炎检查和仔细完成主观调查信息表。⑦无其他严重并发症,如心脏病、高血压、脑梗塞等。⑧自愿参加本试验,并签署知情同意书。

Inclusion criteria

①Meets the diagnostic criteria for lateral epicondylitis.②Age between 18 and 65 years regardless of gender.③Elbow pain duration within 6 months.④Visual Analog Scale (VAS) score for tenderness at the lateral epicondyle ≥ 4.⑤Unilateral elbow involvement.⑥Willing and able to complete all necessary examinations and detailed subjective information forms for lateral epicondylitis.⑦No other severe complications such as heart disease hypertension or stroke.⑧Voluntary participation in the trial with signed informed consent.

排除标准:

①合并有严重心肝肾等脏器肿瘤性病变的患者;②妊娠期妇女和哺乳期妇女;③1周内接受过理疗、针灸、针刀及非甾体抗炎药治疗者;④对针刺排斥,晕针患者;⑤肘关节区域皮肤破损、感染、曾行肘关节手术或上肢畸形及其他可能影响握力的神经肌肉骨骼疾病患者;⑥依从性差,不能完成试验全过程患者。

Exclusion criteria:

①Patients with severe organ tumors such as heart liver or kidney.②Pregnant or breastfeeding women.③Patients who have received physiotherapy acupuncture acupotomy or non-steroidal anti-inflammatory drugs within one week.④Patients who are averse to acupuncture or experience needle syncope.⑤Patients with skin damage infection previous elbow surgery upper limb deformity or other neuromusculoskeletal diseases that may affect grip strength.⑥Poor compliance unable to complete the entire trial.

研究实施时间:

Study execute time:

From 2024-12-01

To      2025-11-21

征募观察对象时间:

Recruiting time:

From 2024-12-02

To      2025-09-21

干预措施:

Interventions:

组别:

观察组

样本量:

35

Group:

Observation group

Sample size:

干预措施:

超声引导下针刺手三里、四渎穴深筋膜层

干预措施代码:

Intervention:

Blade needling at the deep fascia layer of Shousanli (LI10) and Sidu (TE9) points under ultrasound guidance.

Intervention code:

组别:

对照组

样本量:

35

Group:

control group

Sample size:

干预措施:

超声引导下针刺手三里、四渎穴浅筋膜层

干预措施代码:

Intervention:

Blade needling at the superficial fascia layer of Shousanli (LI10) and Sidu (TE9) points under ultrasound guidance.

Intervention code:

样本总量 Total sample size : 70

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang Province

City:

单位(医院):

浙江省立同德医院

单位级别:

三级甲等中西医结合医院

Institution/hospital:

Tongde hospital of Zhejiang Province

Level of the institution:

Grade 3A Integrated TCM & Western Medicine Hospital

测量指标:

Outcomes:

指标中文名:

压痛阈值

指标类型:

主要指标

Outcome:

PPT

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Mayo肘关节功能评分

指标类型:

次要指标

Outcome:

Mayo elbow performance score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉模拟量表

指标类型:

主要指标

Outcome:

Visual Analogue Scale/Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

无痛握力

指标类型:

次要指标

Outcome:

PFG

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

整体疗效评价

指标类型:

附加指标

Outcome:

Overall Efficacy Evaluation

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件记录

指标类型:

副作用指标

Outcome:

Adverse Event Recording

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

This experiment does not require the collection of human specimens

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本实验采用随机对照设计方案,由本项目组成员制定,通过SPSS25.0统计软件产生随机数字表,将观察组、对照组按1:1的比例制备随机卡,装不透光信封密封后备用。具体实施时,将依据纳入/排除标准筛选70例合格病例作为受试对象,按进入研究的先后顺序对应随机卡信封的序号拆封取卡,随机分为观察组和对照组,每组各35例,同时负责招募和评估结果的研究人员不得知随机序列的分配。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study adopted a randomized controlled design developed by the research team. A random number table was generated using SPSS 25.0 statistical software with allocation cards for the intervention and control groups prepared in a 1:1 ratio. These cards were sealed in opaque envelopes sequentially numbered for subsequent use.During implementation 70 eligible participants meeting the inclusion/exclusion criteria were recruited. Subjects were assigned to sequentially numbered envelopes corresponding to their enrollment order. Upon envelope opening participants were allocated to either the intervention group or control group (35 cases per group) according to the pre-prepared randomization cards. To ensure allocation concealment outcome assessors were blinded to group assignment throughout the study period.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.medresman.org.cn/uc/index.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org.cn/uc/index.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本试验采用病床病例观察表采集数据,建立电子数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

In this experiment the sickbed patient observation table was used to collect data and establish an electronic database

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above